Yuh-Lih Chang

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Muscular Dystrophy

Top Venues

Expert review of clinical pharmacology

Journal of thrombosis and thrombolysis

Therapeutic drug monitoring

This page only lists publications with an associated author ORCID identifier.

Publications

Vincent Yi-Fong Su, Ting-Lin Ding, Yuh-Lih Chang, Yueh-Ching Chou, Hsuen-En Hwang, Chian-Ying Chou, Chia-Chen Hsu
Comparative effectiveness and safety of inhaled corticosteroid plus long-acting β 2 -agonist fixed-dose combinations vs. long-acting muscarinic antagonist in bronchiectasis. Expert review of clinical pharmacology 17 (2) (2024)
Vincent Yi-Fong Su, Ting-Lin Ding, Yuh-Lih Chang, Yueh-Ching Chou, Hsuen-En Hwang, Chian-Ying Chou, Chia-Chen Hsu
Comparative effectiveness and safety of inhaled corticosteroid plus long-acting β 2 -agonist fixed-dose combinations vs. long-acting muscarinic antagonist in bronchiectasis. Expert review of clinical pharmacology (2024)
Vincent Yi-Fong Su, Ting-Lin Ding, Yuh-Lih Chang, Yueh-Ching Chou, Hsuen-En Hwang, Chian-Ying Chou, Chia-Chen Hsu
Comparative effectiveness and safety of inhaled corticosteroid plus long-acting β 2 -agonist fixed-dose combinations vs. long-acting muscarinic antagonist in bronchiectasis. Expert review of clinical pharmacology 17 (2) (2024)
Chia-Chen Hsu, Cheng-Chi Chen, Chian-Ying Chou, Kuan-Hsuan Chen, Sheng-Fan Wang, Shih-Lin Chang, Yuh-Lih Chang
Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and advanced kidney disease. Journal of thrombosis and thrombolysis (2023)
Ju-Chieh Wung, Hsin-Chung Lin, Chia-Chen Hsu, Chia-Chieh Lin, Szu-Yu Wang, Shih-Lin Chang, Yuh-Lih Chang
Drug-related problem characterization and the solved status associated factor analysis in a pharmacist-managed anticoagulation clinic. PloS one 17 (8) (2022)
Ying-Yu Huang, Yu-Hsuan Huang, Tsai-Hung Wu, Che-Chuan Loong, Chia-Chen Hsu, Yueh-Ching Chou, Yuh-Lih Chang
Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis. Therapeutic drug monitoring 44 (3) (2022)